

4th Category 1 Focus Group Meeting PLUS – Extended Scope June 4th and 5th 2019

Venue: Embassy Suites by Hilton Alexandria Old Town

1900 Diagonal Road, Alexandria, Virginia 22314, US

www.cat1focusgroup.com

Time	Agenda Topics for Day 1 – June 4 th , 2019
08:15 – 08:30 AM	Welcome Karsten Lindhardt, Egalet and Sebastian Schwier, Grünenthal
08:30 – 09:00 AM	Keynote: The Future of Abuse Deterrent – Where are we going? Speaker
Session I	Category 1 test in the Lab
09:00 – 09:30 AM	Recent trends in Standardization Speaker:– (Chris, Torben)
9:30 – 10:00 AM	Category 1 testing beyond “classical” Opioids (pro-drugs, PEGylated molecules, stimulants) Speaker:
10:00 – 10:30 AM	Coffee and Networking Break
10:30 – 11:00 AM	Emerging Technologies – Vaping Stephen Hoag and Chris Altomare
11:00 – 2:00 AM	Introduction to Working Group 1 – Working Group 4
12:00 – 1:00 PM	Lunch
1:00 – 2:30 PM	Working Sessions <ul style="list-style-type: none"> - Working Group 1 – Standardization: - Working Group 2 – Manipulation methods and new technologies: - Working Group 3 – New Generic ADF guidance Working Group 4 – Statistical Issues with margins introduced with recent guidelines
Session II	Product Specific guidelines
2:30 – 3:00 PM	FDA perspective Speaker
3:00 – 3:30 PM	Generic industry Perspective

4th Category 1 Focus Group Meeting *PLUS* – Extended Scope June 4th and 5th 2019

	Speaker:
3:30 – 4:00 PM	Coffee and Networking Break
4:00 – 4:45 PM	Panel Discussion Sessions I and II – Category 1 Technologies and Product Specific Guidelines Speakers from Sessions I and II
4:45 – 5:00 PM	Wrap up Day 1
6:00 – 8:00 PM	Networking event <i>Location tbd</i>

4th Category 1 Focus Group Meeting PLUS – Extended Scope June 4th and 5th 2019

Time	Agenda Topics for Day 2 – June 5 th , 2019
08:15 – 08:30 AM	Short Welcome
Session III	Safety of Excipients / Category 2&3 Studies
08:30 – 09:00 AM	FDA requirements and thinking regarding safety requirements for excipients used in ADF FDA speaker
09:00 – 9:30 AM	Considerations from the Lab for evaluating excipients in the Category 1 field Speaker
9:30 – 10:00 AM	Statistical issues during Category 2 & 3 Studies Beatrice
10:00 – 10:30 AM	Coffee and Networking Break
Session IV	Real World Data
10:30 – 11:00 AM	FDA perspective on what sort of data required to demonstrate that ADF works FDA speaker
11:00 – 11:30 AM	Payor Perspective: requirements for compelling ADF and Category 1 data Speaker
11:30 – 12:30 PM	Market Access: Recent data from marketed ADF and data demonstrating that ADF works Comparison of the pre-ADF situations for Opioids and Stimulants RADARS speaker
12:30 – 1:30 PM	Lunch
1:30 – 3:00 PM	Working Sessions Presentations Groups 1 & 2 & 3 & 4 And Panel discussion on Safety of Excipients and Realworld Data
3:00 – 3:30 PM	Wrap Up

WE THANK OUR SPONSORS